ARCHIVES

In Brief: VP-16 NDA Approved By FDA Only For Refractory Testicular Cancer; Removed From Group C List

This article is from The Cancer Letter archive.

Vol. 09 No. 46 | December 2, 1983

Download PDF Visit The Full Archive

Related Articles

DeVita Frustrated By Gap Between Bypass, “Real” Budgets, Seeks Better System To Develop Priorites

April 24, 1981

New Evidence Shows Polyp Removal Lowers Death Rate at 23-Year Follow-up

February 24, 2012

NCI CTEP-Approved Trials For the Month of May

May 30, 2014

CDC To Award $23 Mil. To States for Screening

April 26, 1991

CT Finds Early Lung Tumors In Smokers, Former Smokers

March 31, 2006

Study Finds No Evidence That Statins Cut Cancer Risk

January 27, 2006